Civica to Introduce Affordable Long-Acting Insulin Glargine in the US by January 2026
Civica's Affordable Insulin Glargine: A New Hope for Diabetic Patients
In an exciting development for diabetes care, Civica, a nonprofit pharmaceutical company, has announced that it will launch an affordable version of long-acting insulin, known as insulin glargine-yfgn, in the United States starting January 1, 2026. This initiative aims to provide much-needed relief for those burdened by the high costs of diabetes management.
Civica's long-acting insulin will be offered in convenient pre-filled pens and is set to be priced at $45 for a box of five pens. This pricing strategy is expected to significantly undercut current market prices, making insulin more accessible to patients who often face exorbitant costs. Notably, in California, this product will be marketed under the
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.